Yongbo Yu
Overview
Explore the profile of Yongbo Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao K, Wang X, Jin Y, Zhu X, Zhou T, Yu Y, et al.
Cell Death Dis
. 2025 Feb;
16(1):132.
PMID: 40011489
No abstract available.
2.
Zhang M, Yao X, Zhang N, Yu Y, Jia C, Guan X, et al.
Diagn Pathol
. 2025 Jan;
20(1):11.
PMID: 39871307
Background: A number of genetic aberrations are associated with the BCL6-correpresor gene (BCOR), including internal tandem duplications (ITDs) and gene fusions (BCOR::CCNB3 and BCOR::MAML3), as well as YWHAE::NUTM2, which are...
3.
Zhang Z, Liu F, Yu Y, Xie F, Zhu T
PeerJ
. 2024 Dec;
12:e18530.
PMID: 39624133
Background: Bladder cancer is characterized by a high recurrence rate and mortality, posing a significant challenge to clinical management. Recently, cuproptosis, a novel form of regulated cell death, has been...
4.
Shang X, Wang H, Yu Y, Gu J, Zeng J, Hou S
Front Chem
. 2024 Jul;
12:1417715.
PMID: 38979404
Antimicrobial photodynamic therapy (aPDT) has emerged as a highly promising strategy for non-antibiotic treatment of infections due to its unique advantages in efficient bactericidal action and reduction of drug resistance....
5.
Zhang P, Zhong D, Yu Y, Wang L, Li Y, Liang Y, et al.
Biomaterials
. 2024 Jul;
311:122695.
PMID: 38954960
Integrating immunotherapy with nanomaterials-based chemotherapy presents a promising avenue for amplifying antitumor outcomes. Nevertheless, the suppressive tumor immune microenvironment (TIME) and the upregulation of cyclooxygenase-2 (COX-2) induced by chemotherapy can...
6.
Shen C, Liu J, Xie F, Yu Y, Ma X, Hu D, et al.
Cancer Lett
. 2024 Jun;
595:217002.
PMID: 38823761
The mechanism underlying N6-methyladenosine (m6A) modification in bladder cancer (BC) remains elusive. We identified that the RBM15/METTL3 complex enhances m6A modification and promotes the ENO1 protein translation efficiency through its...
7.
Zhang M, Yu Y, Qiu C, Xia X, Sun Y, Wang L, et al.
Med Sci Monit
. 2024 May;
30:e944022.
PMID: 38768093
BACKGROUND The concept of driving pressure (ΔP) has been established to optimize mechanical ventilation-induced lung injury. However, little is known about the specific effects of setting individualized positive end-expiratory pressure...
8.
Zhang R, Yu Y, Yang Y, Zhang M, Zhang X, Chang Y, et al.
Med Oncol
. 2024 May;
41(6):160.
PMID: 38763968
Papillary thyroid carcinoma (PTC) is a common endocrine malignancy. The pathology of PTC is far from clear. As a kinase that can be targeted, the role of TNIK in PTC...
9.
Yu Y, Liang Y, Xie F, Zhang Z, Zhang P, Zhao X, et al.
Cancer Lett
. 2024 May;
593:216964.
PMID: 38762193
Tumor-associated macrophages (TAMs) are important components of the tumor microenvironment (TME) and strongly associated with poor prognosis and drug resistance, including checkpoint blockade immunotherapy in solid tumor patients. However, the...
10.
Xia Q, Yu Y, Zhan G, Zhang X, Gao S, Han T, et al.
J Neuroimmune Pharmacol
. 2024 May;
19(1):17.
PMID: 38717643
In our previous study, we concluded that sirtuin 5 (SIRT5) was highly expressed in microglia following ischaemic stroke, which induced excessive neuroinflammation and neuronal injury. Therefore, SIRT5-targeting interventions should reduce...